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Trials have shown beneﬁts of palifermin in reducing the incidence and severity of oral mucositis in patients
with hematological malignancies undergoing autologous hematopoietic stem cell transplantation (HSCT)
with total body irradiation (TBI)-based conditioning regimens. Similar outcome data are lacking for patients
receiving non-TBIebased regimens. We performed a retrospective evaluation on the pharmacoeconomic
beneﬁt of palifermin in the setting of non-TBIebased conditioning and autologous HSCT. Between January
2002 and December 2010, 524 patients undergoing autologous HSCT for myeloma (melphalan 200 mg/m2)
and lymphoma (high-dose busulfan, cyclophosphamide, and etoposide) as preparative regimen were
analyzed. Use of patient-controlled analgesia (PCA) was signiﬁcantly lower in the palifermin-treated groups
(myeloma: 13% versus 53%, P < .001; lymphoma: 46% versus 68%, P < .001). Median total transplant charges
were signiﬁcantly higher in the palifermin-treated group, after controlling for inﬂation (myeloma: $167,820
versus $143,200, P < .001; lymphoma: $168,570 versus $148,590, P < .001). Palifermin treatment was not
associated with a difference in days to neutrophil engraftment, length of stay, and overall survival and was
associated with an additional cost of $5.5K (myeloma) and $14K (lymphoma) per day of PCA avoided. Future
studies are suggested to evaluate the cost-effectiveness of palifermin compared with other symptomatic
treatments to reduce transplant toxicity using validated measures for pain and quality of life.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Oral mucositis remains one of the most signiﬁcant com-
plications of high-dose chemotherapy and hematopoietic
stem cell transplantation (HSCT). Mucositis results from
damage to the epithelial lining of the oral cavity and ranges
from mild erythema to severe ulceration. Clinical conse-
quences of oral mucositis include pain, dehydration,
malnutrition, and infection [1]. These consequences can lead
to a rise in health care utilization from increased use of opiod
analgesics, increased total parenteral nutrition (TPN), and
prolonged hospitalization [2,3]. Currently, there is no stan-
dard therapy for decreasing the incidence or severity of oral
mucositis in patients undergoing HSCT, but some studies
have shown early promising results in reducing the inci-
dence of oral mucositis in patients undergoing HSCT using
low-level infrared laser therapy or cryotherapy [4,5]. Pal-
ifermin, a recombinant human keratinocyte growth factor, isedgments on page 857.
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agent proven to decrease the incidence and duration of se-
vere oral mucositis in patients with hematological malig-
nancies receiving myelotoxic therapy and HSCT.
The initial label indication of palifermin approved by the
FDA in 2004 was broad and included autologous and allo-
geneic transplant recipients. Among recipients of allogeneic
HSCT from matched related and unrelated donors, results of
a randomized, double-blind, placebo-controlled clinical trial
indicated that palifermin treatment on 3 consecutive days
before myeloablative conditioning and a single dose after
conditioning did not reduce acute graft-versus-host-disease
or the incidence of grades 3 to 4 oral mucositis [6]. In
autologous transplant recipients in a pivotal phase III trial,
administration of palifermin for 3 days before and after total
body irradiation (TBI)-based myeloablative conditioning was
associated with signiﬁcant reductions in the incidence of
World Health Organization (WHO) grades 3 to 4 oral
mucositis, patient-reported outcomes of throat and mouth
soreness, use of opioid analgesics, and use of TPN [7].
A subset analysis of data from the registration trial suggested
that the acquisition cost of palifermin is compensated by
decreased health care resource utilization [8]. Another pub-
lished report from the registration trial also conﬁrmed aTransplantation.
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ifermin based on reduced hospital duration, analgesic use,
and TPN utilization [9].
However, the study results of palifermin use in non-
TBIebased conditioning regimens and autologous HSCT are
unclear. In 2011, the FDA amended the label indication of
palifermin to exclude its use for mucositis prevention with
melphalan 200 mg/m2 as a conditioning regimen. The basis
for this recommendation was a trial from the European
Group for Blood and Marrow Transplantation comparing 3
doses of palifermin (pretransplant conditioning) or 6 doses
(pre/postconditioning) to a placebo armwhere the incidence
of WHO grades 3 to 4 mucositis was not signiﬁcantly
different between the 2 groups [10]. A subsequent trial using
palifermin 3 days before conditioning withmelphalan 200 or
140mg/m2 reported palifermin-treated patients experienced
signiﬁcantly less days of hospitalization and less need for
opioid analgesics, TPN, and blood transfusions [11]. The
conﬂicting data raised the question of utility of palifermin
in autologous HSCTs using non-TBIebased conditioning
regimens.
Based on the initial FDA label indication, palifermin
administration in autologous transplant recipients became a
standard practice at our institution for patients undergoing
non-TBIebased myeloablative conditioning and autologous
HSCT. After the update of the FDA label, our aim was to gain
additional data to support the use of palifermin in this pa-
tient population. We had 2 questions: Is palifermin effective
in reducing mucositis in the setting of autologous HSCT after
non-TBIebased conditioning? If palifermin is effective, what
is its effect on health care resource utilization? To answer
these questions, we undertook a retrospective study of
myeloma and lymphoma patients transplanted after non-
TBIebased conditioning before and after the clinical intro-
duction of palifermin. We hypothesized that palifermin
would be effective in reducing i.v. narcotic use with patient-
controlled analgesia (PCA) (as a surrogate for oral mucositis)
in the setting of non-TBIebased conditioning for patients
undergoing autologous HSCT. We also explored the effect of
palifermin on other clinical parameters, including days to
neutrophil engraftment, overall survival (OS), health care
resource utilization, length of stay (LOS), and charges
incurred during speciﬁed time periods before and after HSCT.
METHODS
Study Design
This single-center, retrospective study compared palifermin-treated
patients with untreated control subjects for prespeciﬁed end points
among patients receiving high-dose chemotherapy and autologous HSCT.
Institutional review board approval was obtained to use patient data for this
analysis.
Patients
The patient population included 254 myeloma and 270 lymphoma pa-
tients who underwent autologous HSCT at our institution between January
2002 and December 2010, for a total of 524 patients. The treatment group
comprised consecutive patients treated with palifermin from May 2005
until December 2010. The control group 164 patients treated before FDA
approval of palifermin (January 2002 to April 2005) and 31 patients trans-
planted after the FDA approval of palifermin who did not receive palifermin
for various reasons, including physician discretion or patient declination due
to associated costs or logistics of palifermin administration. To make the
data less ambiguous and minimize bias, inclusion criteria were restricted to
patients receiving uniform conditioning regimens of melphalan 200 mg/m2
for myeloma patients and high-dose busulfan, cyclophosphamide, and
etoposide for lymphoma patients. Patients who had received a prior autol-
ogous or allogeneic transplant or enrollment in any clinical trial using
investigational drugs were excluded from analysis. Palifermin-treated pa-
tients were identiﬁed through an automated analysis of pharmacy records.According to standard institutional practice at our institution, palifermin is
administered per the label indication for a total of 6 doses, 60 mg/kg/day i.v.
for 3 consecutive days before receiving conditioning regimen and 3 doses
post-HSCT. Those patients who received at least 3 of 6 planned doses of
palifermin were included in the analyses in the palifermin-treated group.
Statistical Methods
Myeloma and lymphoma patients were analyzed separately using SAS
version 9.3. Baseline characteristics, including sex, age, ethnicity, and dis-
ease status at transplant, and primary diagnosis for lymphoma patients
were compared between the palifermin and control groups. Differences
were assessed using Fisher’s exact test or the Kruskal-Wallis test. Disease
status at transplant was classiﬁed into 3 categories based on treatment
response according to the deﬁnitions established by the American Society
for Blood and Marrow Transplantation and the Center for International
Blood and Marrow Transplant Research.
Because of the nature of our study and the inherent limitations associ-
ated with a retrospective analysis, the primary end point used in this
analysis was duration of i.v. narcotic use with PCA as a surrogate for severe
oral mucositis. Because of inconsistencies in the grading of oral mucositis,
we could not use WHO grade 3 or 4 oral mucositis of as our primary end
point. Days of PCA use were calculated based on the number of days i.v.
narcotics with a PCA pump was used during the transplant hospitalization.
The duration was considered to be zero days among patients who did not
use i.v. narcotics with a PCA pump.
Other end points included clinical outcomes, days to neutrophil
engraftment, OS, health care resource utilization, LOS, and charges incurred
during speciﬁed time periods before and after HSCT. Days to neutrophil
engraftment was deﬁned as the number of days from date of transplant to
date of absolute neutrophil count recovery, where absolute neutrophil count
recovery is deﬁned as .5  109/L for 3 consecutive laboratory values ob-
tained on different days. OS was deﬁned at the time from transplantation to
the last follow-up or death irrespective of the cause of death. The Kaplan-
Meier method was used to estimate the probabilities of OS, and the log-
rank test was used to test for differences between groups. LOS was
deﬁned as the number of days of hospitalization for HSCT.
Charges were used as a surrogate for cost. Differences in the ratio of
costs to charges among hospitals or among different diseases were not
relevant because we were only interested in comparing costs between
treatment groups at our center. Charges were deﬁned as all charges gener-
ated for professional or technical items or services during a speciﬁed time
period and were adjusted for inﬂation using a standard inﬂation rate
determined for each disease group. Inﬂation factors for the actual charges
for myeloma and lymphoma patients were calculated separately, because
the rate of increase in charges varied according to adoption of disease-
speciﬁc supportive care protocols (Supplementary Figure 1). The calcu-
lated inﬂation factors for myeloma and lymphoma patients were 1.07 and
1.04, respectively. The year 2010 was used as the base year. Charges were
grouped into 3 time periods: (1) 5 days before admission for transplant,
capturing the charges for the 3 daily injections of palifermin administered
before conditioning, which were typically given in the outpatient setting;
(2) admission date to 30 days post-transplant, encompassing generally all
transplant-related charges; and (3) 31 days post-transplant to 100 days
post-transplant, capturing long-term follow-up charges. The charges from
the 3 groups were summarized as total charges from 5 days before admis-
sion to 100 days post-transplant.
Multivariable analysis using generalized linear models was conducted
for each outcome to compare treatment groups. Cox proportional hazards
regressionwas used for OS, ANCOVA for days to neutrophil engraftment and
LOS, logistic regression for incidence of PCA use, and negative binomial
regression for duration of PCA use and charges due to their skewed distri-
butions. Models were adjusted for differences in baseline characteristics.
RESULTS
The median age of myeloma patients at the time of HSCT
was 59 years in the palifermin group versus 57 years in the
control group. The lymphoma cohort was younger compared
with the myeloma cohort, and age between the palifermin
group versus the control subjects was not signiﬁcantly
different (48 years versus 47 years; P ¼ .22). All baseline
characteristics were similar in the palifermin and control
groups for both myeloma and lymphoma patients, except for
disease status in the lymphoma patients (Table 1).
The incidence of PCA use was signiﬁcantly lower among
the palifermin group than among the control group for both
myeloma and lymphoma patients (myeloma: 13% versus
Table 1
Baseline Characteristics of Patients
Characteristic Myeloma Lymphoma
Palifermin (n ¼ 162) Control (n ¼ 92) P Palifermin (n ¼ 167) Control (n ¼ 103) P
Sex .37
Female 80 (49) 35 (38) .09 60 (36) 43 (42)
Male 82 (51) 57 (62) 107 (64) 60 (58)
Age, yr .22
Median 59 57 .06 48 47
Range 27-76 27-76 18-72 19-69
Ethnicity
White 90 (57) 61 (66) .14 113 (69) 76 (74) .41
Disease status at transplant .02
At least VGPR 17 (10) 10 (11) .97 62 (37) 47 (46)
Partial response (1, 2, or 3þ) or stable disease 128 (79) 74 (80) 83 (50) 34 (33)
Primary refractory, progressive, or relapse 16 (10) 8 (9) 22 (13) 22 (21)
Diagnosis .30
Hodgkin lymphoma d d 59 (35) 43 (42)
Non-Hodgkin lymphoma d d 108 (65) 60 (58)
Values are number of cases, with percents in parentheses, unless otherwise indicated. VGPR indicates very good partial response.
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tively) (Table 2). Similarly, the median duration of PCA use
was shorter among the palifermin group (myeloma: 0 days
versus 3 days, P < .001; lymphoma: 0 days versus 5 days,
P ¼ .002, respectively) (Table 2). The median time to
neutrophil engraftment and LOS were not different
comparing the palifermin with the control groups for both
myeloma and lymphoma patients (Table 2).
As expected, both myeloma and lymphoma patients who
received palifermin had a higher median charge during the
5-day pretransplant period (myeloma: $12,800 versus $1010,
P < .001; lymphoma: $8160 versus 0; P < .001) (Table 2).
Similar trends were seen with charges associated from the
day of admission to day 30 post-transplant (myeloma:
$144,280 versus $118,920, P < .001; lymphoma: $152,000Table 2
Health Care Resource Utilization
Variable Myeloma
Palifermin (n ¼ 162) Control (n ¼ 92)
Incidence of PCA use,y n (%) 20 (13) 45 (53)
Duration of PCA use,y d
Mean .6 3.7
Median 0 3
Neutrophil engraftment, d
Mean 13.2 13.6
Median 13 13
LOS, d
Mean 17.2 18.0
Median 17 18
Charges, U.S.$z
5 days preadmission
Mean 13,590 6410
Median 12,800 1010
Admission date, day þ30
Mean 150,860 124,070
Median 144,280 118,920
Day þ31 to day þ100
Mean 10,600 27,170
Median 9820 13,930
Total charges
Mean 175,050 157,640
Median 167,820 143,200
* Adjusted for baseline characteristics.
y Missing PCA data (myeloma: 3 patients in palifermin group and 7 in control g
z Adjusted for inﬂation to 2010 charge rates.versus $131,150, P < .001). Interestingly, median charges
from day 31 to day 100 were lower in the palifermin-treated
group in both myeloma and lymphoma patients compared
with the control group (myeloma: $9820 versus $13,930,
P < .001; lymphoma: $8420 versus $11,200, P < .135), even
though in aggregate, median charges for the palifermin-
treated group were higher than the corresponding median
charges for the control group (myeloma: $167,820 versus
$143,200, P < .001; lymphoma: $168,570 versus $148,590,
P < .001) (Table 2).
Figure 1 illustrates the distribution of charges adjusted to
2010 levels for myeloma patients (Figure 1A) and lymphoma
patients (Figure 1B). Of note, the overall peak of the distri-
bution of charges shifted to the right for the palifermin-
treated patients compared with the control group, but theLymphoma
P* Palifermin (n ¼ 167) Control (n ¼ 103) P*
<.001 75 (46) 64 (68) <.001
.002
<.001 2.5 4.6
0 5
.10
.16 12.0 12.4
12 12
.34
.14 22.5 21.9
22 22
<.001 9820 2240 <.001
8160 0
<.001 160,720 135,950 <.001
152,000 131,150
<.001 17,520 20,640 .135
8420 11,200
<.001 188,050 158,830 <.001
168,570 148,590
roup; lymphoma: 3 patients in palifermin group and 9 in control group).
Figure 1. Distribution of charges in (A) myeloma and (B) lymphoma patients.
Figure 2. Overall Survival in (A) myeloma and (B) lymphoma patients.
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very high adjusted total charges not seen in palifermin-
treated patients.
OS was not different in the palifermin-treated and control
groups for both myeloma (Figure 2A) and lymphoma
(Figure 2B) patients. Figures 3 and 4 illustrate the breakdown
of itemized charges according to categories for myeloma and
lymphoma, respectively. Of note, the fraction of charges
related to pharmacy was larger in the palifermin-treated
group of myeloma patients (43% of charges) compared with
the nonpalifermin-treated myeloma patients (32% of
charges), whereas there was not a corresponding increase in
pharmacy charges comparing palifermin-treated versus
control lymphoma patients. The larger increase in pharmacy
charges seen in the palifermin-treated myeloma patients
reﬂects other changes in supportive care among morerecently transplanted myeloma patients, including the
protocol-speciﬁed use of post-transplant granulocyte
colony-stimulating factor, a practice change that did not
occur in lymphoma patients undergoing autologous
transplant.
DISCUSSION
Oral mucositis is a frequent complication experienced by
patients who undergo HSCT and may affect as many as 75% of
all HSCT recipients [12,13]. In this patient population, oral
mucositis is typically associatedwith increased risks of serious
infection and increased use of TPN, antibiotics, and pain
medication [3,14]. These complications can be costly. Pal-
ifermin has been shown to decrease the severity of oral
mucositis and its subsequent outcomes in patients undergo-
ing autologous HSCT after TBI-based conditioning regimens.
However, the published data surrounding the effects of pal-
ifermin in non-TBIebased conditioning regimens are incon-
sistent. Our large retrospective analysis provides insight on
the impact of palifermin administration on clinical outcomes
and health care resource utilization in the setting of autolo-
gous HSCT after non-TBIebased conditioning regimens.
Clinically, palifermin administration in patients under-
going HSCT resulted in a signiﬁcant decrease in the incidence
of parenteral narcotics administered through PCA and also
decreased the duration of PCA utilization in the palifermin-
treated cohorts among both myeloma and lymphoma pa-
tients. The reduction in the incidence and duration of PCA
use in the palifermin-treated group suggests that these pa-
tients experienced less pain, likely due to oralmucositis, than
Figure 3. Pie charts of adjusted charges 5 days before admittance to 30 days after admittance for myeloma patients.
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rameters of neutrophil engraftment and LOS are similar in
both cohorts for both disease groups. These results support
the administration of palifermin for decreasing severity of
mucositis in the setting of autologous HSCT after non-
TBIebased conditioning regimens.
From an economic perspective, using charges generated
over a wide range of years adjusted to 2010 levels, we found
that palifermin administration was associated with a signif-
icant increase of total charges both in the preadmission phase
of outpatient palifermin administration and during the hos-
pitalization for transplant admission. These higher charges
are likely related to the acquisition costs of palifermin and
the associated administration costs. The results conﬂict with
the published data on health care utilization in the registra-
tion trial population. Studies using the patient population
from the phase III trial, on which the FDA based approval for
palifermin for this particular indication, suggested that the
acquisition cost of palifermin is offset by decreased health
care resource utilization [8,9]. Analysis of a large number of
patients in our institutional database indicates this was not
the case. Palifermin administration was associated with a
signiﬁcant increase in total charges related to transplantation
independent of inﬂation of overall health care charges.
Charges related to follow-up post-transplant (day þ31 to
day þ100) were lower in the palifermin-treated groups. This
may reﬂect the less long-term sequelae of oral mucositis in
the control group or changes in practice in more recent yearsFigure 4. Pie charts of adjusted charges 5 days before admittaassociated with earlier transfer of patients out of the health
care system (where charges were captured) back to their
local referring oncologist (where charges were not captured).
However, the equivalent OS between the palifermin and
control groups suggest no signiﬁcant impact of severity of
mucositis on survival.
Strengths of our study include the sample size and uni-
formly treated myeloma and lymphoma patient populations.
However, certain limitations, including the retrospective na-
ture of analysis and the need to adjust charges for inﬂation to
facilitate comparison of charges across a broad range of
transplant dates, limit the impact of our ﬁndings to recom-
mend change in practice. Additional limitations include the
lack of uniform clinical scoring of mucositis that was
compensated by the use of PCA as a surrogate end point of
incidence of severe oral mucositis. PCAs are commonly used
for pain management associated with oral mucositis and
represent our standard institutional practice for treating pain
associatedwith severe oralmucositis. Thus, despite the lack of
WHO mucositis scores, we believe the use of PCA as a surro-
gate for severemucositis supports thesigniﬁcant clinical effect
of palifermin in the setting of non-TBIebased conditioning.
In conclusion, palifermin is associated with a reduction in
PCA use and an associated reduction in severe mucositis.
However, there is a cost for prevention of pain and suffering
associated with severe mucositis. To provide a perspective for
future research in this area, we have estimated the costs
associated with each day of severe pain avoided by using daysnce to 30 days after admittance for lymphoma patients.
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inﬂation to 2010 rates, the average cost of palifermin admin-
istration was $17,409 (myeloma) and $29,221 (lymphoma),
which translates to an additional cost of $5,511 (myeloma) and
$13,792 (lymphoma) per day of PCA use (severe pain) avoided.
From a patient perspective, reduction in a day of severe
mucositis that requires treatment with parenteral narcotics
with a PCA may be worth the additional daily charges. Further
research is suggested to evaluate the cost-effectiveness of pal-
ifermin use compared with other symptomatic treatments that
reduce transplant toxicities using validated measures for pain
and quality of life.
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